ACTINIUM PHARMACEUTICALS, INC. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amortization, Percent
ACTINIUM PHARMACEUTICALS, INC. (ATNM) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amortization, Percent of 4.18% for the 12-month period ending 2012-12-31, per its 10-K filed 2014-02-28.
Discontinued › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseAmortization · last filed 2014-02-28
- ACTINIUM PHARMACEUTICALS, INC. effective income tax rate reconciliation, nondeductible expense, amortization, percent for fiscal 2012 was 4.18%, a 156.44% increase from fiscal 2011.
- ACTINIUM PHARMACEUTICALS, INC. effective income tax rate reconciliation, nondeductible expense, amortization, percent for fiscal 2011 was 1.63%.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amortization, Percent 12 month |
|---|---|
| 2012-12-31 | 4.18% 10-K · filed 2014-02-28 |
| 2011-12-31 | 1.63% 10-K · filed 2013-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 |